Martin Drew

Recent data from the AGENT™ DCB post-approval study demonstrates that AGENT DCB shows in-hospital safety outcomes comparable to DES in patients with ISR. This evidence reinforces clinical confidence in AGENT without compromising safety. Learn more about the study: qrco.de/bgkwwW AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1

Step into what’s next in Interventional Cardiology at #EuroPCR 2026. See how new evidence in #ModernPCI, LAAC and Pulmonary Embolism translates into real‑world practice. Choose from 3 symposia and 50+ expert‑led sessions: bostonsci.co/HeJxXvPsk2b #BSCEMEA

OACs may present challenges for patients and the physicians who treat them. Are OACs worth the risk? Or is there a better option? WATCHMAN™ is the first and only #LAAC device to demonstrate non-inferior efficacy and superior safety profile to DOACs. ⁴ Break the pattern of OACs and provide stroke protection beyond the prescription. Learn more at qrco.de/bggteO WATCHMAN FLX Pro Left Atrial Appendage Closure Device Indications, Safety, and Warnings: qrco.de/bg3esL

Registration is now OPEN for the AHP Annual Conference 2026 🎉 Join one of the UK’s largest dedicated meetings for nurses and allied health professionals working in the cath lab. 🔹 Core & Advanced learning streams 🔹 Hands-on demonstrations 🔹 Practical, team-focused education 🔹 Conference dinner included Free for BCIS members Accommodation bursaries are available for eligible attendees. Be the first to register here: millbrook-events.co.uk/BCISAHP2026

Improved IVUS-guided PCI outcomes support critical clinical decisions. In a recent publication, Dr. Simon Walsh outlines the IVUS 123 Workflow, a simplified, standardized approach designed to support intuitive decision-making, reproducibility, and long-term PCI durability. 📄Read more: qrco.de/bgbY7m

Good morning from #BCISACI Day Two in the Education Zone! This morning, @jdinaus and @JenARossington are teaming up for the Boston Scientific Breakfast Symposium, Streamlining IVUS-Guided PCI Workflow: Driving Efficiency with ALA. There is still time to join. The session is located in the Exhibition area on the 3rd Floor of the West Wing.

The ShortCUT trial data shows that WOLVERINE™ Cutting Balloon™ demonstrated significant cost savings in total procedural costs compared to IVL. See the cost comparison: qrco.de/bgYRjJ WOLVERINE Coronary Cutting Balloon Indications, Safety, and Warnings: qrco.de/WOLVERINE

Designed with intent, AGENT™ DCB leverages Paclitaxel’s intrinsic properties — hydrophobic, lipophilic, and structurally optimized — to deliver drug efficiently and durably. • Hydrophobic for minimized drug loss during delivery • Lipophilic for rapid absorption into fatty tissue • Sharp-edge structure for improved tissue penetration Explore AGENT™ DCB: qrco.de/bgWBVK AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1

Pre-clinical data showed that AGENT™ DCB’s sharp-edge Paclitaxel coating enabled deeper tissue penetration compared to ‘Limus DCB’s spherical coating morphology. 📊The result: improved drug delivery efficiency at the tissue level — achieved through design, not chance. Learn more about the science behind AGENT™ DCB: qrco.de/bgWBVK AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1

AGENT™ DCB delivered 2.3x more drug into tissue than 'Limus DCB in pre-clinical testing, and also showed 67% fewer downstream particulates than 'Limus DCB in bench testing. By pairing Paclitaxel’s hydrophobic, lipophilic properties with a sharp-edge structure, AGENT™ DCB delivers higher transfer and less downstream. See what makes AGENT™ DCB different: qrco.de/bgWBVK AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1

See how imaging + vessel prep drive success in PCI with AGENT™ DCB. Top interventional cardiologists walk through key clinical cases. 🎥View the full case on EDUCARE: qrco.de/bgHo3m AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1

Transforming PCI with #IVUS! Discover how it enhances patient outcomes and leads to higher long-term survival rates. 🔗 Explore our clinical data: qrco.de/bgI5uD

📢 The AGENT DCB STANCE Trial has commenced! This trial is designed to assess the safety and efficacy of AGENT™ Drug-Coated Balloon in de novo coronary lesions. Learn more: qrco.de/bgBZDz CAUTION: Investigational Device in de novo lesions. Limited by Federal (or US) law to investigational use only. Safety and effectiveness has not been established in de novo lesions.

Did you miss the Integration of CT and IVUS for Treatment of Coronary Artery Disease in Daily Practice at #EuroPCR 2025? Access the full replay here: bostonsci.co/w4IFUTP7fVb @sbrugaletta demonstrated how CT imaging and IVUS can improve planning and execution of PCI.

Precision Meets Innovation in Coronary Interventions Watch Dr. Joost Daemen demonstrate AVVIGO™+ in a real-world case of LAD bifurcation in a 72-year-old patient. Watch the full case on EDUCARE: bostonsci.co/TZeXpv19LSb #InterventionalCardiology #AVVIGO+ #PCI #EDUCARE #IVUS

At #CRT2025, in study results from Dr. @hect2701 and team, automated IVUS-guided lesion assessment with AVVIGO™+ ALA™ demonstrated high concordance with experts. Learn more: bit.ly/3EgeMjc Safety info: bit.ly/42e94pY

We have officially closed the acquisition of @BoltIVL. We look forward to advancing the intravascular lithotripsy (IVL) therapy developed by Bolt which will complement our cardiovascular portfolio by expanding treatment options for coronary and peripheral disease. $BSX

Have you already submitted your IVUS-guided case applying WOLVERINE™ ? If you haven’t, #ShowUsYourCuttingEdge by showcasing your case for a chance to be part of the #EuroPCR 2025 expert talk. Learn how to participate here: bostonsci.co/NIMtceoLURb #BSCEMEA #ModernPCI

How would you like a chance to present your case at EuroPCR? Have I captured your interest? Click below to find out more… #ShowUsYourCuttingEdge

Have you already shared your WOLVERINE™ case with us? If not, #ShowUsYourCuttingEdge by submitting your IVUS-guided WOLVERINE™ case for a chance to be part of the #EuroPCR 2025 expert talk. Discover how to participate here: bostonsci.co/HmI2LBGwxRb